Author:
Gao Jia C,Wu Albert G,Contento Marissa N,Maher Jacqueline M,Cline Abigail
Reference22 articles.
1. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
2. Otezla [Full Prescribing Information]. Celgene Corporation, Summit, NJ. Available from: https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf. Accessed November 10, 2021.
3. Apremilast: A Review in Psoriasis and Psoriatic Arthritis
4. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
5. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献